|
1
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Abridged republication of FIGO's staging classification
for cancer of the ovary, fallopian tube, and peritoneum. Cancer.
121:3452–3454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rossing MA, Wicklund KG, Cushing-Haugen KL
and Weiss NS: Predictive value of symptoms for early detection of
ovarian cancer. J Natl Cancer Inst. 102:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng X, Chen S, Li L, Liu X, Liu X, Dai
S, Zhang P, Lu H, Lin Z, Yu Y and Li G: Evaluation of HE4 and TTR
for diagnosis of ovarian cancer: Comparison with CA-125. J Gynecol
Obstet Hum Reprod. 47:227–230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han C, Bellone S, Siegel ER, Altwerger G,
Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A,
Riccio F, et al: A novel multiple biomarker panel for the early
detection of high-grade serous ovarian carcinoma. Gynecol Oncol.
149:585–591. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferreira JA, Magalhães A, Gomes J, Peixoto
A, Gaiteiro C, Fernandes E, Santos LL and Reis CA: Protein
glycosylation in gastric and colorectal cancers: Toward cancer
detection and targeted therapeutics. Cancer Lett. 387:32–45. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dall'Olio F, Malagolini N, Trinchera M and
Chiricolo M: Sialosignaling: Sialyltransferases as engines of
self-fueling loops in cancer progression. Biochim Biophys Acta.
1840:2752–2764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Biskup K, Braicu EI, Sehouli J, Tauber R
and Blanchard V: The ascites N-glycome of epithelial ovarian cancer
patients. J Proteomics. 157:33–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodrigues JG, Balmaña M, Macedo JA, Poças
J, Fernandes Â, de-Freitas-Junior JCM, Pinho SS, Gomes J, Magalhães
A, Gomes C, et al: Glycosylation in cancer: Selected roles in
tumour progression, immune modulation and metastasis. Cell Immunol.
333:46–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuzmanov U, Musrap N, Kosanam H, Smith CR,
Batruch I, Dimitromanolakis A and Diamandis EP: Glycoproteomic
identification of potential glycoprotein biomarkers in ovarian
cancer proximal fluids. Clin Chem Lab Med. 51:1467–1476. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alley WR Jr, Vasseur JA, Goetz JA, Svoboda
M, Mann BF, Matei DE, Menning N, Hussein A, Mechref Y and Novotny
MV: N-linked glycan structures and their expressions change in the
blood sera of ovarian cancer patients. J Proteome Res.
11:2282–2300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shetty V, Nickens Z, Shah P, Sinnathamby
G, Semmes OJ and Philip R: Investigation of sialylation aberration
in N-linked glycopeptides by lectin and tandem labeling (LTL)
quantitative proteomics. Anal Chem. 82:9201–9210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shetty V, Hafner J, Shah P, Nickens Z and
Philip R: Investigation of ovarian cancer associated sialylation
changes in N-linked glycopeptides by quantitative proteomics. Clin
Proteomics. 9:102012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mikami M, Tanabe K, Matsuo K, Miyazaki Y,
Miyazawa M, Hayashi M, Asai S, Ikeda M, Shida M, Hirasawa T, et al:
Fully-sialylated alpha-chain of complement 4-binding protein:
Diagnostic utility for ovarian clear cell carcinoma. Gynecol Oncol.
139:520–528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsuo K, Tanabe K, Ikeda M, Shibata T,
Kajiwara H, Miyazawa M, Miyazawa M, Hayashi M, Shida M, Hirasawa T,
et al: Fully sialylated alpha-chain of complement 4-binding protein
(A2160): A novel prognostic marker for epithelial ovarian
carcinoma. Arch Gynecol Obstet. 297:749–756. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen KC, Sung PL, Hsieh SL, Chou YT, Lee
OK, Wu CW and Wang PH: α2,3-sialyltransferase type I regulates
migration and peritoneal dissemination of ovarian cancer cells.
Oncotarget. 8:29013–2902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Christie DR, Shaikh FM, Lucas JA IV, Lucas
JA III and Bellis SL: ST6Gal-I expression in ovarian cancer cells
promotes an invasive phenotype by altering integrin glycosylation
and function. J Ovarian Res. 1:32008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mikuła-Pietrasik J, Uruski P, Szubert S,
Szpurek D, Sajdak S, Tykarski A and Książek K: Malignant ascites
determine the transmesothelial invasion of ovarian cancer cells.
Int J Biochem Cell Biol. 92:6–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szender JB, Emmons T, Belliotti S, Dickson
D, Khan A, Morrell K, Khan AN, Singel KL, Mayor PC, Moysich KB, et
al: Impact of ascites volume on clinical outcomes in ovarian
cancer: A cohort study. Gynecol Oncol. 146:491–497. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Orr B and Edwards RP: Diagnosis and
treatment of ovarian cancer. Hematol Oncol Clin North Am.
32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng J, Huang H, Shan Y, Li Y, Jin Y and
Pan L: The effect of CA125 nadir level on survival of
advanced-stage epithelial ovarian carcinoma after interval
debulking surgery. J Cancer. 8:3410–3415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Webber K and Friedlander M: Chemotherapy
for epithelial ovarian, fallopian tube and primary peritoneal
cancer. Best Pract Res Clin Obstet Gynaecol. 41:126–138. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu N, Mei L, Fan X, Tang C, Ji X, Hu X,
Shi W, Qian Y, Hussain M, Wu J, et al: Phosphodiesterase 5/protein
kinase G signal governs stemness of prostate cancer stem cells
through Hippo pathway. Cancer Lett. 378:38–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maji S, Panda S, Samal SK, Shriwas O, Rath
R, Pellecchia M, Emdad L, Das SK, Fisher PB and Dash R: Chapter
three-Bcl-2 antiapoptotic family proteins and chemoresistance in
cancer. Adv Cancer Res. 137:37–75. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ween MP, Armstrong MA, Oehler MK and
Ricciardelli C: The role of ABC transporters in ovarian cancer
progression and chemoresistance. Crit Rev Oncol Hematol.
96:220–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuchenbaecker KB, Hopper JL, Barnes DR,
Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE,
Milne RL, Andrieu N, et al: Risks of breast, ovarian, and
contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
JAMA. 317:2402–2416. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chudecka-Głaz A, Cymbaluk-Płoska A,
Wężowska M and Menkiszak J: Could HE4 level measurements during
first-line chemotherapy predict response to treatment among ovarian
cancer patients? PLoS One. 13:e01942702018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Britain CM, Holdbrooks AT, Anderson JC,
Willey CD and Bellis SL: Sialylation of EGFR by the ST6Gal-I
sialyltransferase promotes EGFR activation and resistance to
gefitinib-mediated cell death. J Ovarian Res. 11:122018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schultz MJ, Swindall AF, Wright JW, Sztul
ES, Landen CN and Bellis SL: ST6Gal-I sialyltransferase confers
cisplatin resistance in ovarian tumor cells. J Ovarian Res.
6:252013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Zhang Y, Lin H, Liu Y, Tan Y, Lin
J, Gao F and Lin S: Alpha2,3-sialyltransferase III knockdown
sensitized ovarian cancer cells to cisplatin-induced apoptosis.
Biochem Biophys Res Commun. 482:758–763. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geisler C and Jarvis DL: Effective
glycoanalysis with Maackia amurensis lectins requires a clear
understanding of their binding specificities. Glycobiology.
21:988–993. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bennun SV, Hizal DB, Heffner K, Can O,
Zhang H and Betenbaugh MJ: Systems glycobiology: Integrating
glycogenomics, glycoproteomics, glycomics, and other ‘omics data
sets to characterize cellular glycosylation processes. J Mol Biol.
428:3337–3352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu J, Xie X, Nie S, Buckanovich RJ and
Lubman DM: Altered expression of sialylated glycoproteins in
ovarian cancer sera using lectin-based ELISA assay and quantitative
glycoproteomics analysis. J Proteome Res. 12:3342–3352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng WK and Oon CE: How glycosylation
aids tumor angiogenesis: An updated review. Biomed Pharmacother.
103:1246–1252. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Pan C, Zhou L, Cai Z, Zhao S and
Yu D: Knockdown of ST6Gal-I increases cisplatin sensitivity in
cervical cancer cells. BMC Cancer. 16:9492016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goldberg JM, Piver MS, Hempling RE and
Recio FO: Paclitaxel and cisplatin combination chemotherapy in
recurrent epithelial ovarian cancer. Gynecol Oncol. 63:312–317.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
du Bois A, Lück HJ, Meier W, Möbus V,
Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, et
al: Carboplatin/paclitaxel versus cisplatin/paclitaxel as
first-line chemotherapy in advanced ovarian cancer: An interim
analysis of a randomized phase III trial of the Arbeitsgemeinschaft
Gynäkologische Onkologie Ovarian Cancer Study Group. Semin Oncol.
24 (5 Suppl 15):S15-44–S15-52. 1997.
|
